News

Read our latest news, and find more about us and our portfolio companies.

2021/09/03
Altoida Unveils New Brand Identity with Reimagined Logo and Website

Refreshed brand identity reflects Altoida’s emphasis on data and humanity, and will support the company’s growth as the world leader in Precision Neurology

2021/07/08
Theolytics expands Series A financing and welcomes M Ventures as a new investor

Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team.

2021/05/17
Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures

Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers Company's proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more efficacious tumor targeted therapy Seasoned leadership to steer company's growth and pipeline development

2021/04/22
Anavo Therapeutics Launches with EUR 20 Million Seed Financing to Create Industry-Leading Pipeline of Allosteric Phosphatase Modulators

Seed round was led by M Ventures and INKEF Capital, and co-led by Taiho Ventures and Bioqube Ventures

2021/04/01
FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer

FoRx Therapeutics announces the appointment of Tarig Bashir as Chief Executive Officer

2021/03/08
STORM Therapeutics Expands Scientific Advisory Board with the Appointment of Professor Tsutomu Suzuki

STORM Therapeutics today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB)

2021/03/03
FORENDO PHARMA SUCCESSFULLY COMPLETES PHASE 1 STUDIES OF FOR-6219 IN ENDOMETRIOSIS, AIMING TO ADVANCE PROGRAM INTO PHASE 2 CLINICAL STUDIES

Forendo Pharma today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook

2021/02/24
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline

• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors • Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic • Two investigational new drug (IND) applications planned in 2021

2021/02/11
Artios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients

* Artios Pharma transitions to a clinical-stage precision medicine company * Advances next generation DNA Damage Response (DDR) treatment targeting ATR in patients with advanced or metastatic solid tumors

2021/01/21
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders

Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders - Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board